TPST (Tempest Therapeutics) Float Percentage Of Total Shares Outstanding: 46.78% (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPST Tempest Therapeutics Inc TPST
31 GF Score
Price $1.02
! 1 Warning Sign
View Full Analysis

What is Tempest Therapeutics Float Percentage Of Total Shares Outstanding?

Tempest Therapeutics TPST -13.99% 31 Float Percentage Of Total Shares Outstanding is 46.78% as of Aug. 15, 2026. GuruFocus rates TPST with a GF Score™ of 31/100. The stock has 1 warning sign investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Tempest Therapeutics's float shares is 7.48 Mil. Tempest Therapeutics's total shares outstanding is 15.98 Mil. Tempest Therapeutics's float percentage of total shares outstanding is 46.78%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Tempest Therapeutics's Insider Ownership is 31.48%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Tempest Therapeutics's Institutional Ownership is 5.31%.

TPST
31GF Score
Tempest Therapeutics Inc TPST
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Tempest Therapeutics Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Tempest Therapeutics's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=7.48/15.98
=46.78%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 46.78% mean?
Tempest Therapeutics (TPST) has a Float Percentage Of Total Shares Outstanding of 46.78% as of Aug. 15, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Tempest Therapeutics and its competitors.
Is Tempest Therapeutics' Float Percentage Of Total Shares Outstanding too high?
Tempest Therapeutics' current Float Percentage Of Total Shares Outstanding is 46.78%. Overall, Tempest Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Tempest Therapeutics' Float Percentage Of Total Shares Outstanding compare to ICU and INTI?
Tempest Therapeutics' Float Percentage Of Total Shares Outstanding of 46.78% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Tempest Therapeutics and its competitors. Tempest Therapeutics's current Float Percentage Of Total Shares Outstanding is 46.78%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tempest Therapeutics stock overvalued right now?
Tempest Therapeutics (TPST) has a current Float Percentage Of Total Shares Outstanding of 46.78%. The current Float Percentage Of Total Shares Outstanding is 46.78%. Tempest Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Tempest Therapeutics (TPST), the current Float Percentage Of Total Shares Outstanding is 46.78% as of Aug. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tempest Therapeutics Business Description

Address 2000 Sierra Point Parkway, Suite 400, Brisbane, CA, USA, 94005
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets. Company's small-molecule product candidate, amezalpat (previously known as TPST-1120), has completed a Phase 2 study in first-line hepatocellular carcinoma and the second small-molecule product candidate is TPST-1495, plans to initiate a Phase 2 study for in familial adenomatous polyposis.
31GF Score

Get the complete analysis for TPST

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.02
Price